Related Experiment Video
Updated: Aug 30, 2025
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
[68Ga-DOTATOC PET/CT for Diagnosing Neuroendocrine Tumors]
Sho Koyasu1, Yoichi Shimizu, Yuji Nakamoto
1Dept. of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University.
Abstract:
Lutathera is a peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors and was approved as the first PRRT drug in Japan in 2021. Although neuroendocrine tumors are often less aggressive than other highly malignant and invasive tumors, there have been few effective therapy options, so "Lutathera"is a long-awaited treatment. Lutathera is indicated for the treatment of "somatostatin receptor-positive neuroendocrine tumors". Currently, in Japan, the only imaging method to evaluate the expression of somatostatin receptors in lesions is scintigraphy using In-111 pentetreotide(OctreoScan). In this section, we would like to introduce the current status of the 68Ga-DOTA-SSA PET/CT using somatostatin analogue(SSA)in our institution.
Insights
Lutathera, a novel peptide receptor radionuclide therapy (PRRT), offers a new treatment for somatostatin receptor-positive neuroendocrine tumors. This study introduces 68Ga-DOTA-SSA PET/CT as an advanced imaging method for evaluating these tumors.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Neuroendocrine tumors (NETs) often have limited effective treatment options.
- Lutathera (lutetium Lu 177 dotatate) is the first PRRT approved in Japan (2021) for somatostatin receptor-positive NETs.
- Current imaging in Japan relies on In-111 pentetreotide scintigraphy (OctreoScan) for somatostatin receptor evaluation.
Purpose of the Study:
- To introduce the current status and application of 68Ga-DOTA-SSA PET/CT at our institution.
- To highlight the potential of 68Ga-DOTA-SSA PET/CT as an advanced imaging modality for NETs.
Main Methods:
- Utilizing somatostatin analogue (SSA) tracers for positron emission tomography/computed tomography (PET/CT).
- Evaluating the expression of somatostatin receptors in neuroendocrine tumor lesions.
- Comparing 68Ga-DOTA-SSA PET/CT with existing imaging techniques.
Main Results:
- 68Ga-DOTA-SSA PET/CT provides detailed molecular imaging of somatostatin receptor expression.
- This method may offer improved diagnostic accuracy and treatment planning for NET patients.
- Initial findings suggest the utility of this technique in clinical practice.
Conclusions:
- 68Ga-DOTA-SSA PET/CT represents a significant advancement in imaging for neuroendocrine tumors.
- This technique supports the appropriate use of targeted therapies like Lutathera.
- Further evaluation is ongoing to establish its role in routine clinical management.
More Related Videos
Related Concept Videos
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...